Highest-materiality recent filing
Maximus Q3 adjusted EPS $2.22 beats $2.16 YoY; cuts FY2026 guidance on federal contract modification
Revenue $1.28B vs $1.35B prior year; diluted EPS $1.95 (adjusted $2.22) vs $1.86 ($2.16).
Maximus adds $325M term B loans to repurchase stock and repay revolving debt
New Tranche B-1 Term Loans of $325M entered on May 27, 2026; same terms as existing term B loans.
Maximus Q2 EPS beats estimates, raises FY2026 guidance, authorizes $400M buyback
Revenue $1.31B (vs $1.36B YoY); diluted EPS $1.80, adjusted $2.07 (vs $2.01 YoY).
50,864,001 shares (93.2% of outstanding) represented at March 10, 2026 annual meeting.
Maximus Q1 adj EPS $1.85 beats prior $1.61; raises FY2026 guidance
Revenue $1.35B (-4.1% YoY), in-line with expectations; GAAP EPS $1.70 vs $0.69, adj EPS $1.85 vs $1.61.
Maximus Chief Legal Officer John Martinez resigns effective Feb 15, 2026
John T. Martinez, Chief Legal Officer and Corporate Secretary, notified Maximus of his resignation on Dec 15, 2025.
Full year revenue $5.43B (+2.4% YoY); organic growth 3.9% driven by U.S. Federal clinical programs.
Maximus board authorizes $400M stock purchase program expansion
Board increased aggregate authorization to $400M, inclusive of $32.7M remaining under prior program.
Maximus Q3 FY2025 EPS $1.86 ($2.16 adj); raises full-year guidance
Revenue $1.35B (+2.5% YoY); organic growth 4.3% led by U.S. Federal Services (11.4% growth).
Maximus amends bylaws to enhance shareholder proposal disclosure requirements
Shareholders must disclose derivative instruments held within past 24 months and performance-related fees tied to stock value.
Maximus Q2 FY2025: EPS $1.69 (adj. $2.01); raises FY revenue/earnings guidance
Revenue $1.36B (+1.0%); adjusted EPS $2.01 vs $1.57 YoY; organic growth 3.0%.
Maximus adds $250M Tranche A-1 Term Loans to existing credit facility
New Tranche A-1 Term Loans of $250M aggregate principal, same terms as existing term A loans.
Maximus 2025 annual meeting: all directors elected, auditor ratified, say-on-pay approved
All 8 director nominees elected with 48.5M to 49.5M votes for; broker non-votes ~1.66M.
Maximus Q1 revenue up 5.7% to $1.40B, raises FY25 adjusted EPS guidance to $5.90-$6.20
Adjusted diluted EPS $1.61 vs $1.34 YoY; GAAP EPS $0.69 includes $38M divestiture charges from Australia/South Korea sales.
Maximus board authorizes $200M increase to stock purchase program
Previous $200M authorization (June 2024) fully consumed; $171.4M remained as of Sep 30, 2024.
Maximus dismisses EY as auditor, appoints KPMG for FY2025
Audit Committee dismissed Ernst & Young effective Nov 25, 2024, following a competitive selection process.
CMS cancelled the CCO solicitation covering 1-800-MEDICARE and Federal Marketplace; no immediate re-solicitation planned.
Maximus FY2024 revenue up 8.2% to $5.31B; adj. EPS $6.11; FY2025 guidance $5.70-$6.00
Full year FY2024 revenue $5.31B (+8.2% YoY); diluted EPS $4.99; adjusted diluted EPS $6.11.
Maximus Q3 FY2024 revenue $1.31B (+10.6%), adj. EPS $1.74, raises FY guidance for third time
Revenue $1.31B (+10.6% YoY), diluted EPS $1.46, adjusted diluted EPS $1.74 (vs $0.50 and $0.78).
Maximus expands stock buyback program to $200M aggregate
Board authorized $200M stock purchase program, including $6M remaining from prior authorization.
Maximus amends credit agreement, extends maturities and increases revolver to $750M
Tranche A term loans reduced to $650M (from $868.1M), maturity extended to May 2029.
Maximus Q2 revenue up 11.7% to $1.35B, adjusted EPS $1.57; raises FY24 guidance
Revenue $1.35B (+11.7% YoY); organic growth 12.6%; adjusted EPS $1.57 vs $0.81 prior year.
Maximus shareholders elect all eight directors; reject shareholder proposal
All eight director nominees elected with >98% of votes cast in favor; 94.6% of outstanding shares represented.
Maximus announces departure of Teresa Weipert, General Manager U.S. Federal Services
Teresa A. Weipert, General Manager of U.S. Federal Services, departing the company effective February 27, 2024.
Maximus Q1 revenue $1.33B (+6.2%); raises FY24 EPS and FCF guidance
Revenue $1.33B (organic +6.9%); diluted EPS $1.04, adjusted EPS $1.34 vs $0.65/$0.94 YoY.
Maximus reports Q4/FY2023 results; FY2024 guidance $5.05-5.2B revenue, adj. EPS $5.05-5.35
FY2023 revenue $4.90B (+5.9% YoY), adj. diluted EPS $3.83; Q4 revenue $1.26B (+7.0%), organic growth 7.4%.
Revenue $1.19B, +5.6% YoY; organic growth 6.7% driven by U.S. segments.
Maximus reports MOVEit breach affecting 8-11M individuals; records $15M expense
Unauthorized third party exploited MOVEit zero-day; accessed personal info of 8 to 11 million individuals.
Maximus will hold annual advisory votes on executive compensation after shareholder approval
Shareholders voted at March 14, 2023 annual meeting to hold annual say-on-pay votes; company adopts policy.
Maximus Q2 FY2023 EPS down; reaffirms FY guidance; debt reduced $275M
Q2 revenue $1.21B (+2.5% YoY); diluted EPS $0.52, adjusted EPS $0.80 (vs $0.80 and $1.07 prior year).
Maximus adds proxy access, updates advance notice; shareholders elect all directors
New bylaw allows shareholder or group of up to 20 owning 3% for 3 years to nominate up to 2 or 20% of directors.
Maximus General Counsel David Francis to retire at end of 2023
David Francis, General Counsel since 1998, plans to retire at end of 2023.
Maximus Q1 beats, raises FY23 guidance on restart of Medicaid redeterminations
Q1 revenue $1.25B (+8.5% YoY); organic growth 10.3%; adjusted EPS $0.94, down from $1.12.
Maximus FY22 rev $4.63B, adj EPS $4.37; FY23 rev guide $4.75-4.90B, adj EPS $3.70-4.00
FY22 revenue $4.63B, up 8.9% YoY; diluted EPS $3.29, adjusted EPS $4.37 (vs $5.19 prior year).
Maximus Q3 FY2022 revenue $1.13B, EPS $0.51; cuts FY2022 EPS guidance on $11.7M write-down
Revenue $1.13B, down $118M YoY; normalized organic growth ~21% ex COVID response work.
Maximus unveils 3-5 year strategy: mid-single-digit organic growth, 10-14% adj. op. margin
Targets $150B addressable market growing at ~6% over next 3-5 years; three growth pillars: Customer Services Digitally Enabled, Future of Health, Advanced Technologies.
Maximus Q2 rev $1.18B (+22.7%); cuts FY22 EPS guidance to $3.00-$3.50 amid PHE delays
Revenue $1.18B (+22.7% YoY); organic flat; normalized organic ~20% excluding COVID work.
92.7% of outstanding shares (57.4M) represented at March 15, 2022 annual meeting.
Maximus Q1 rev $1.15B (+21.7%), raises FY22 rev guidance to $4.5-4.7B; adj EPS flat
Revenue $1.15B, up 21.7% YoY; COVID-19 response work $120M, down $40M YoY.
Maximus appoints David Mutryn as CFO and Theresa Golinvaux as PAO effective Dec 1, 2021
David Mutryn appointed CFO; base salary $475,000, EBP target 65% of salary.
Maximus corrects prior 8-K: fiscal 2021 EPS guidance range is $4.00-$4.30
Amended 8-K fixes error in Nov 22 filing: forecasted 2021 EPS guidance correctly stated as $4.00–$4.30 per share.
Maximus FY21 revenue $4.25B (+23%), EPS $4.67; FY22 guidance revenue $4.4-4.6B
Revenue $4.25B (+22.9% YoY) driven by $1.1B COVID-19 response work and $322.7M from Attain Federal and VES acquisitions.
Maximus board chair Peter Pond resigns; John Haley appointed as non-executive chair
Peter B. Pond resigned from Maximus board on Sept 14, 2021; served as director since 1997 and chair since 2001.
Maximus reports record Q3 revenue of $1.24B, raises FY21 guidance
Revenue $1.24B (+38% YoY); GAAP EPS $1.51, adjusted EPS $1.66.
VES 2020 net revenue $364.7M, net income $52.2M (14.3% margin); 2019 net income $71.2M (20.3% margin).
Maximus CFO Nadeau to retire Nov 30 with consulting; GM Romeo retires with $861.5K payout
CFO Richard Nadeau retires Nov 30, 2021; equity awards continue vesting; consulting retainer $11,000/month through May 31, 2022.
On February 27, 2024, Maximus, Inc. (the “Company”) announced that Teresa A. Weipert, General Manager, U.S. Federal Services is departing the Company.
David Francis, who has served as the General Counsel of Maximus since 1998, has announced his intention to retire at the end of 2023.
Also effective December 1, 2021, Maximus appointed Theresa Golinvaux, age 47, as its Principal Accounting Officer.
the Company appointed David Mutryn as its Chief Financial Officer and Principal Financial Officer to replace Richard Nadeau.
On September 14, 2021, Peter B. Pond resigned from the Maximus board of directors.
The board of directors appointed John J. Haley as the independent, non-executive Chair to replace Mr. Pond as well as the Chair of the Compensation Committee.
In addition, director Anne K. Altman was appointed Vice Chair of the board of directors.
Maximus previously disclosed the planned retirement of its Chief Financial Officer, Richard J. Nadeau, effective November 30, 2021.
Maximus previously disclosed the retirement of Thomas Romeo from his role as U.S. Federal Services Segment General Manager effective July 31, 2021.
Max materiality 0.85 · Median 0.70 · Most common event earnings